Ireland Research And Markets released a report detailing the growth of the Glucagon-like Peptide 1, or GLP-1, market which is predicted to grow at a CAGR of 6.48% during the projected period of 2022-2027.
"The glucagon-like peptide 1 market is set for growth due to one main driving factor: rising diabetes rates", according to a Cision's PR Newswire article. Diabetes, caused by a lack of insulin in the body and a failing pancreas, is a chronic disease where the body cannot correctly use insulin. GLP-1 can significantly help lower blood sugar levels in those with type 2 diabetes. It can increase insulin production and limit glucagon production, thus reducing glucose in the bloodstream. Higher numbers of low and middle-income countries have led to rapidly growing diabetes prevalence, boosting global GLP-1 market growth.
"Glucagon-like peptide 1 is called an incertin", said Your Hormones online. This hormone stimulates more insulin creation. GLP-1 comes from pre-proglucagon, a broken-up polypeptide, and its result is similar to glucagon hence its name "glucagon-like". The primary function of GLP-1 is promoting more insulin release and inhibiting glucagon release. These actions lead to increasing fullness feelings during and after meals easing diabetic issues.
According to their online About Us page, Research and Markets says it is the world’s largest market research store providing data and insights for over 450 clients across 800 different industries and markets. Founded in 2002 with its headquarters next to the Guinness Brewery in Dublin, Ireland, they offer a wide range of data covering multitudes of industries from Automotive to Telecommunications to Zoology.